"Modelis is a drug discovery biotech focused on accelerating therapeutic development for rare genetic disorders. Our unique and validated platform translates drugs from bench-to-bedside faster, more efficiently, and more cost-effectively than conventional approaches. Modelis? approach relies on genetically-conserved small animal models, such as C. elegans nematodes and zebrafish, which are genetically modified using CRISPR/Cas9 to mimic patient, specific disease-causing mutations. These patient ?avatars? are then used to better understand the underlying mechanisms of these rare disorders, and to find effective therapeutics against them. By screening compounds in vivo, Modelis is able to rapidly find therapeutics that are safe, effective, and bioavailable, and that have a high translational potential."